ElrySign

Executive Summary

ErlySign (CURO Biosciences Pvt Ltd) is an Indian preclinical-stage diagnostics company developing a non-invasive, saliva-based test for early oral cancer detection. Leveraging AI-driven biomarker analysis and CRISPR-Cas13a sensing, the test delivers results within 15 minutes, targeting affordable rapid screening for hospitals, labs, and dental clinics. Oral cancer is a major health burden in India, where late diagnosis contributes to high mortality; ErlySign's approach aims to enable point-of-care screening at a fraction of current costs. Founded in 2020 and based in Nagpur, the company has raised $1.8 million to advance its technology through preclinical validation. ErlySign's saliva-based platform avoids the discomfort and expense of tissue biopsies, and the integration of AI enhances specificity and sensitivity. With global oral cancer rates rising, a rapid, accurate, and non-invasive diagnostic could significantly improve early detection and outcomes, particularly in resource-limited settings. The company is currently focused on completing preclinical studies and scaling its manufacturing capabilities.

Upcoming Catalysts (preview)

• Q4 2026Completion of preclinical validation study and publication of results70% success
• Q2 2027Series A financing round to fund first-in-human studies60% success
• Q1 2027Strategic partnership with dental clinic chain or hospital network for pilot testing50% success